Effect of weather on temporal pain patterns in patients with temporomandibular disorders and migraine

Patients with masticatory muscle pain and migraine typically report that the intensity of pain fluctuates over time and is affected by weather changes. Weather variables, such as ambient temperature and humidity, may vary significantly depending on whether the individual is outdoor or indoor. It is, therefore, important to assess these variables at the individual level using portable monitors, during everyday life. This study aimed to determine and compare the temporal patterns of pain in individuals affected with facial and head pain and to investigate its relation with weather changes. Eleven patients (27·3 ± 7·4 years) with chronic masticatory muscle pain (MP) and twenty (33·1 ± 8·7 years) with migraine headache (MH) were asked to report their current pain level on a visual analogue scale (VAS) every hour over fourteen consecutive days. The VAS scores were collected using portable data-loggers, which were also used to record temperature, atmospheric pressure and relative humidity. VAS scores varied markedly over time in both groups. Pain VAS scores fluctuate less in the MP group than in the MH group, but their mean, minimum and maximum values were higher than those of migraine patients (all P < 0·05). Pain scores <2 cm were more common in the MH than in the MP group (P < 0·001). Perceived intensity of pain was negatively associated with atmospheric pressure in the MP group and positively associated with temperature and atmospheric in the MH group. Our results reveal that patients with masticatory muscle pain and patients with migraine present typical temporal pain patterns that are influenced in a different way by weather changes

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18\u20134.74, p = 0.015) with increased risk of severe COVID-19. Recent use (&lt;1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20\u201312.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the sensitivity analyses. Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pandemic persists. ANN NEUROL 2021;89:780\u2013789

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR&nbsp;=&nbsp;2.05, 95%CI&nbsp;=&nbsp;1.39–3.02, p&nbsp;&lt;&nbsp;0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR&nbsp;=&nbsp;0.42, 95%CI&nbsp;=&nbsp;0.18–0.99, p&nbsp;=&nbsp;0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon

Short-term Effects of a First-Line Treatment Including Counseling and Self-Management Strategies on Chronic TMD Muscle Pain and Awake Bruxism in Women

Aims: To evaluate the short-term effects of a standardized first-line noninvasive approach (FL-A) including counseling and self-management strategies on pain, masticatory muscle tenderness, and awake bruxism in women with chronic temporomandibular disorder myalgia (mTMD) and to test whether patients' trait anxiety predicted their response to treatment. Methods: FL-A was administered to 14 women with chronic mTMD (mean age ± SD = 33.8 ± 11.1 years; 8 with Graded Chronic Pain Scale [GCPS] grade I and 6 with grade II). Its effects on facial pain, masticatory muscle tenderness, and spontaneous awake bruxism episodes were evaluated using questionnaires, surface electromyography, and quantitative sensory testing. General linear models were used to test FL-A efficacy after 1 (T1) and 2 (T2) months. Results: FL-A reduced pain (from baseline [T0] to T2, P = .010), the frequency of awake bruxism episodes (T0 to T1, P = .024), and their intensity by about 30% (T0 to T1, P < .001). Pressure pain thresholds at the masticatory muscle locations increased significantly from T0 to T2 (P < .001). Patients' trait anxiety decreased significantly from T0 to T2 (P = .030). Trait anxiety measured at baseline was not correlated with relative changes in pain (T0 to T2, P = .248). Conclusion: In the short term, FL-A reduces facial pain, masticatory muscle tenderness, and awake bruxism in women with chronic mTMD with low disability. A conservative management strategy should be prioritized for the initial management of these patients

Mandibular rest position and electrical activity of the masticatory muscles.

The determination of a correct vertical dimension of occlusion is a critical procedure in clinical dentistry.The objectives of this study were to analyze the relation between mandibular rest position and electrical activity of masticatory muscles and to compare clinical and electromyographic rest position in subjects with different vertical facial morphologic features.Clinical rest position and electromyographic rest position were investigated in 40 subjects. Electromyographic rest position ranged from 0.4 to 12.7 mm (average 7.7 +/- 2.7 mm). Clinical rest position ranged from 0.1 to 4.4 mm (average 1.4 +/- 1.1 mm). The average difference between electromyographic rest position and clinical rest position was 6.3 +/- 2.5 mm (range 0.3 to 10.3 mm). Sixteen subjects were selected according to the Frankfort mandibular plane angle and separated in two groups having a mandibular plane angle > or = 28 degrees.Rest position was significantly greater (p < 0.05) in the low-angle group (2 +/- 1.3 mm) than in the high angle group (0.8 +/- 0.8 mm). Electromyographic rest position did not differ between subjects with different facial morphologic features (8.1 +/- 1.7 mm low-angle group; 7.6 +/- 4.1 mm high angle group). By varying the vertical dimension millimeter by millimeter, masseter and anterior temporal electromyographic activity demonstrated a considerable decrease over an interocclusal distance of 3 to 4 mm. Further mandibular opening up to 18 mm corresponded to small changes in postural activity.This study suggests that a jaw posture with a few millimeters of interocclusal distance involves a great reduction of masticatory muscle activity

Numerical analysis and measures, for the evaluation of comfort – inside buses used for public transportation

Abstract This work analyses the thermo hygrometric conditions inside buses used for public transport. The technical solutions found through the analysis of the thermo-hygrometric conditions inside trains, were also set out and extended to buses. This was in order to maximize the conditioning system and the installation of the air distribution terminals. A pattern for the simulation of the thermo fluid dynamics has been researched, in order to evaluate possible improvements in the conditioning system or in the distribution system. The summer time is the most critical period in the Year for public transport. This fact is due to the frequent opening of doors which makes the internal temperature uneven, due to the strong air drafts. It is also important to assess the cooling transition which can often be long and unbearable for passengers inside. The simulation pattern produced with Airpack 2.1 (Fluent) software, was then validated with a series of measures and used for the analysis of the main issues concerning discomfort. It was also used for the finalization of the improvements. This assessment addresses the fundamental problem that takes place at a bus stop when passengers exit and enter. It has been compared to the solution studied for installing doors equipped with air screens (or air screened doors). The thermo fluid dynamic results guarantee a significant improvement in thermo-hygrometric comfort

PERFORMANCE SIMULATION OF A PASSIVE AIR CONDITIONING SYSTEM FOR REMOTE LOCATIONS

Perth - Western Australi